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Editorial
Who should take aspirin for primary prophylaxis of coronary
heart disease?
Aspirin is widely used for its analgesic and anti-
inflammatory properties, and increasingly in recent years
as antithrombotic treatment. Daily doses of 75–150 mg
eVectively inhibit the ability of blood platelets to synthesise
thromboxane A2 and stable prostaglandins during their
lifespan in the circulation (7–10 days), resulting in inhibi-
tion of platelet function ex vivo (impaired platelet aggrega-
tion) and in vivo (prolonged skin bleeding time). Because
platelets play an important role in thrombosis, aspirin has
an antithrombotic eVect.
Systematic reviews of randomised controlled trials of
antiplatelet drugs (usually aspirin) have shown clinically
worthwhile reductions in cardiovascular events (non-fatal
myocardial infarction, stroke, and cardiovascular death)
when these agents are used in the treatment of patients
with acute ischaemia (myocardial infarction, unstable
angina, stroke), when used as secondary prophylaxis in
patients with chronic ischaemia (previous myocardial infarc-
tion, stroke or transient cerebral ischaemic attacks; stable
angina; peripheral arterial disease), and when used as
prophylaxis in patients with atrial fibrillation.1 2 Antiplatelet
treatment (usually with aspirin) is therefore recommended
as prophylaxis of cardiovascular disease in these patient
groups in national, evidence based guidelines in Scotland3
and the rest of the UK.4 However, as with all eVective
drugs, aspirin has adverse eVects.
Adverse eVects of aspirin
True aspirin allergy is rare. As with other non-steroidal
anti-inflammatory drugs, inhibition by aspirin of gastro-
intestinal prostaglandin synthesis commonly causes upper
gastrointestinal symptoms including dyspepsia, nausea,
and vomiting, peptic ulceration, and bleeding. The risk of
a major gastrointestinal bleed is increased by about 1 in
250 patient years, even with low dose or modified release
aspirin.5 Inhibition of renal prostaglandin synthesis may
also impair renal function, especially in patients with renal
artery stenosis and those receiving angiotensin converting
enzyme inhibitor treatment. The antiplatelet eVect of aspi-
rin impairs primary haemostasis, resulting in increased risk
not only of gastrointestinal bleeding but also of bruising
and nosebleeds, postoperative bleeding, and haemorrhagic
stroke (the risk of which is increased by about 1 in 2500
patient years6).
While these adverse eVects of aspirin are generally
outweighed by its antithrombotic benefits in secondary
prophylaxis of cardiovascular disease, the balance of risks
and benefits must be carefully judged when aspirin is pre-
scribed (or taken as self medication) for primary
prophylaxis of cardiovascular disease. Because of their
lower baseline thrombotic risk, such patients will experi-
ence less absolute benefit from aspirin than patients with
evidence of cardiovascular disease, for a similar level of
relative risk reduction. At the same time the adverse eVects
of aspirin appear unrelated to thrombotic risk, hence such
patients experience a lower ratio of antithrombotic benefit
to risk of adverse eVects (including bleeding) compared to
patients with cardiovascular disease.
Long term aspirin in primary prevention of
coronary heart disease: what risk threshold merits
treatment?
In this issue, Sanmuganathan and colleagues7 report a sys-
tematic review of the benefit and harm from aspirin treat-
ment as long term primary prophylaxis, to determine the
cardiovascular and coronary risk thresholds at which ben-
efit in primary prevention of myocardial infarction exceeds
harm from serious bleeding. They also sought to determine
the absolute benefit, expressed as number needed to treat,
to prevent myocardial infarction, net of bleeding complica-
tions, at diVerent levels of coronary risk. They identified
four randomised controlled trials for meta-analysis. The
coronary heart disease event risk in the control groups var-
ied from 0.36–1.33%, while the cardiovascular event risk
ranged from 0.67–1.17%. There was no heterogeneity
between trials for the end points of cardiovascular events,
stroke or all cause mortality. There was significant
heterogeneity for myocardial infarction (p = 0.03), which
the authors postulated might be caused by diVerences in
study populations or design, or might be a chance observa-
tion. The analysis was continued despite this heterogeneity.
It showed significant reductions overall in all cardiovas-
cular events (by 15%) and in myocardial infarction (by
30%), a non-significant reduction in all cause mortality (by
6%), and a non-significant increase in stroke incidence (by
6%). These results are similar to those in another recent
analysis.8 The rate of bleeding varied widely in control
groups (because of varying definition); however, there was
no significant heterogeneity between trials, and overall
there was a significant increase in bleeding risk (by 69%).
Relating absolute benefit (cardiovascular event reduc-
tion) to absolute risk (increased bleeding), the authors7
observed that at coronary event risks of 1.5% per year, the
five year number needed to treat was 44 to prevent a myo-
cardial infarction, and 77 to prevent a myocardial
infarction net of any important bleeding complication.
They suggest that at lower coronary event rates, aspirin is
not worthwhile (or sometimes harmful in that bleeding risk
exceeds antithrombotic benefit).
Sanmuganathan and colleagues are to be congratulated
on this analysis. It is hard to argue with their conclusion
that advice on aspirin for primary prophylaxis of
cardiovascular disease requires formal estimation of abso-
lute coronary event risk; this is now accepted as best prac-
tice for all methods of prophylaxis, including lifestyle
advice and prescription of drugs for reducing smoking,
blood pressure, and blood cholesterol.4 Their recommen-
dation is consistent with that of current national guidelines
within the UK. In Scotland, the SIGN (Scottish Intercol-
legiate Guideline Network) guideline recommends that
“aspirin (75 mg/day) should be considered for primary
prophylaxis of myocardial infarction in men and women at
high risk (for example, 2% per year) balanced against the
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increased risk of bleeding”.3 The guideline for the rest of
the UK4 is more vague: “aspirin (75 mg) is recommended
in individuals who are older than 50 years and are either
well controlled hypertensive patients or men at high risk of
CHD [coronary heart disease]”.
As might be expected, the authors, who have previously
advocated a “SheYeld table” to identify a 3% annual risk
of CHD for consideration of statin prescription, advocate
another “SheYeld table” to identify a 1.5% annual risk of
CHD for aspirin prescription. The relative merits of diVer-
ent CHD risk prediction equations or tables remains a
controversial topic. I suspect that many doctors and nurses
will prefer systems which, rather that predicting “cut-oVs”,
predict the absolute risk of coronary and/or cardiovascular
events in an individual patient, then use this as a basis to
discuss an individual approach to primary prophylaxis,
considering the whole range of eVective interventions
including aspirin, as well as the individual’s risks of adverse
eVects and their preferences, after informed discussion.
In addition, doctors should advise their patients who
take regular aspirin to reduce their risk of cardiovascular
events, but those whose risk of CHD is less than 1% per
year should be advised that the adverse eVects of aspirin
may outweigh its benefits.
What patient characteristics, apart from absolute
CHD risk, should influence prescription or advice
on aspirin?
Subgroup analysis in one of the four trials of aspirin in pri-
mary prophylaxis (in US physicians) raised the possibility
that aspirin may have been more eVective in those aged 50
years or more, and when cholesterol concentrations were
low rather than high.9 Subgroup analysis in another of the
four trials (in UK general practice) did not confirm this
hypothesis, but raised the possibility that aspirin may have
been more eVective in those with low rather than high
blood pressure.10 These subgroup analyses should be
viewed with caution, because they are retrospective, based
on small numbers of events, hypothesis generating, and
await hypothesis testing in future systematic reviews,
including data from studies in progress.8 Meta-analysis of
secondary prevention trials of aspirin and other antiplatelet
agents has not shown significant diVerences in subgroups.1
In addition to standard contraindications, caution is
required when considering prescription of aspirin to
patients at increased risk of gastrointestinal bleeding (for
example, active dyspepsia, previous peptic ulcer without
eradication of Helicobacter pylori) or intracranial bleeding
(for example, uncontrolled hypertension6). Many patients
at increased risk of CHD are hypertensive, and it is sensi-
ble to control this before regular aspirin use.4
One subgroup who may benefit particularly from
primary aspirin prophylaxis are those with asymptomatic
evidence of atherosclerosis. In the ongoing AAA (aspirin in
asymptomatic atherosclerosis) trial, men and women aged
50–79 years who have no clinical evidence of cardiovas-
cular disease, but have an ankle-brachial systolic blood
pressure index less than 0.95 (which is associated with
increased cardiovascular risk, independent of classical risk
factors11), are randomised to low dose aspirin or placebo.
The results are expected in 2005.
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